Cantor Fitzgerald Cuts Humana Target to $201, Leaves Rating Neutral Amid Membership Uncertainty
Cantor Fitzgerald reduced its price target on Humana to $201 from $290 while keeping a Neutral rating, saying the stock is likely to be range-bound until the company obtains clearer membership data in mid-2026. Multiple other analysts have trimmed targets or downgraded the insurer amid concerns around Medicare Advantage cost and enrollment dynamics…